Online inquiry

IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11053MR)

This product GTTS-WQ11053MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets EGFR&LGR5 gene. The antibody can be applied in Colorectal Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001346897.2; NM_001277226.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1956; 8549
UniProt ID Q504U8; O75473
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11053MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10919MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MABT5102A
GTTS-WQ13257MR IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA PF-05335810
GTTS-WQ2876MR IVTScrip™ mRNA-Anti-CCR4, AMG-761(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG-761
GTTS-WQ512MR IVTScrip™ mRNA-Anti-IGHE, 47H4(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA 47H4
GTTS-WQ5298MR IVTScrip™ mRNA-Anti-ALCAM, CD166 AADC(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CD166 AADC
GTTS-WQ9330MR IVTScrip™ mRNA-Anti-TNFRSF18, INCAGN-01876(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA INCAGN-01876
GTTS-WQ8692MR IVTScrip™ mRNA-Anti-F3, HuMax-TF(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA HuMax-TF
GTTS-WQ9903MR IVTScrip™ mRNA-Anti-CSF2, KB-003(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA KB-003
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW